Roche says Biosite infringes two patents:
This article was originally published in Clinica
Roche Diagnostics has filed two patent infringement complaints against Biosite in a district court in Indiana. San Diego-based Biosite says the allegations, which refer to a device for separating plasma or serum from whole blood and analysing it and biosensing meter technology for use during the process, are without merit, and that it will contest the claims. Biosite recently reported a 43% increase in revenues to $61m and a 61% rise in net income to $10m as sales of its cardiovascular and drug screening products continued to expand.
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.